Augmentation strategies in obsessive-compulsive disorder

Expert Review of Neurotherapeutics

Volumn 13, Issue 2, 2013, Pages 187-203

  Arumugham, Shyam Sundar ^a   Reddy, Janardhan Yc ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

antidepressants; Antipsychotics; Augmentation; Cognitive behavior therapy; Glutamate antagonists; Obsessive compulsive disorder; Psychosurgery; Repetitive transcranial magnetic stimulation; SSRI; Treatment resistant

Indexed keywords

ARIPIPRAZOLE; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DEXAMPHETAMINE; FLUVOXAMINE; GLYCINE; GRANISETRON; HALOPERIDOL; INOSITOL; KETAMINE; LAMOTRIGINE; LITHIUM; LORAZEPAM; MEMANTINE; MIRTAZAPINE; MORPHINE; OLANZAPINE; ONDANSETRON; PINDOLOL; PLACEBO; PREGABALIN; QUETIAPINE; RILUZOLE; RISPERIDONE; SARCOSINE; TOPIRAMATE; TRAZODONE; UNINDEXED DRUG;

BRAIN DEPTH STIMULATION; COGNITIVE THERAPY; DROWSINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; META ANALYSIS; NEUROSURGERY; NEUROTRANSMISSION; OBSESSIVE COMPULSIVE DISORDER; POSITRON EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; REVIEW; SCHIZOTYPAL PERSONALITY DISORDER; SEDATION; SIDE EFFECT; SUPPLEMENTARY MOTOR AREA; SYSTEMATIC REVIEW; TIC; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; MEDLINE; OBSESSIVE-COMPULSIVE DISORDER; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS;

EID: 84873144632     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.12.160     Document Type: Review

References (120)

1. Torres AR, Lima MC. Epidemiology of obsessive-compulsive disorder: a review. Rev. Bras. Psiquiatr. 27(3), 237-242 (2005). (Pubitemid 41337490)
2. McGuire JF, Lewin AB, Horng B, Murphy TK, Storch EA. The nature, assessment, and treatment of obsessive-compulsive disorder. Postgrad. Med. 124(1), 152-165 (2012).
3. Micali N, Heyman I, Perez M et al. Long-term outcomes of obsessive-compulsive disorder: follow-up of 142 children and adolescents. Br. J. Psychiatry 197(2), 128-134 (2010).
4. Gururaj GP, Math SB, Reddy JY, Chandrashekar CR. Family burden, quality of life and disability in obsessive compulsive disorder: an Indian perspective. J. Postgrad. Med. 54(2), 91-97 (2008). (Pubitemid 351724190)
5. Kohn R, Saxena S, Levav I, Saraceno B. The treatment gap in mental health care. Bull. World Health Organ. 82(11), 858-866 (2004). (Pubitemid 39573744)
6. Blanco C, Olfson M, Stein DJ, Simpson HB, Gameroff MJ, Narrow WH. Treatment of obsessive-compulsive disorder by U.S. psychiatrists. J. Clin. Psychiatry 67(6), 946-951 (2006). (Pubitemid 44049093)
7. Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J. Clin. Psychopharmacol. 22(3), 309-317 (2002). (Pubitemid 34546847)
8. Soomro GM, Altman D, Rajagopal S, Oakley-Browne M. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst. Rev. 1, CD001765 (2008).
9. Math SB, Janardhan Reddy YC. Issues in the pharmacological treatment of obsessive-compulsive disorder. Int. J. Clin. Pract. 61(7), 1188-1197 (2007). (Pubitemid 46934618)
10. Rosa-Alcázar AI, Sánchez-Meca J, Gómez-Conesa A, Marín-Martínez F. Psychological treatment of obsessive-compulsive disorder: a meta-analysis. Clin. Psychol. Rev. 28(8), 1310-1325 (2008).
11. Kripke C. Low glycemic diets for obesity treatment. Am. Fam. Physician 77(11), 1534 (2008).
12. Pallanti S, Hollander E, Bienstock C et al.; International Treatment Refractory OCD Consortium. Treatment non-response in OCD: methodological issues and operational definitions. Int. J. Neuropsychopharmacol. 5(2), 181-191 (2002). (Pubitemid 34669829)
13. Goodman WK, Price LH, Rasmussen SA et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, andreliability. Arch. Gen. Psychiatry 46(11), 1006-1011 (1989). (Pubitemid 19278229)
14. Ferrão YA, Shavitt RG, Bedin NR et al. Clinical features associated to refractory obsessive-compulsive disorder. J. Affect. Disord. 94(1-3), 199-209 (2006). (Pubitemid 44093041)
15. Jenike MA, Rauch SL. Managing the patient with treatment-resistant obsessive compulsive disorder: current strategies. J. Clin. Psychiatry 55, 11-17 (1994). (Pubitemid 24113070)
16. Mishra B, Sahoo S, Mishra B. Management of treatment-resistant obsessive-compulsive disorder: an update on therapeutic strategies. Annals of Indian Academy of Neurology 10(3), 145 (2007).
17. Denys D, Mantione M, Figee M et al. Deep brain stimulation of the nucleus accumbens for treatment-refractory obsessive-compulsive disorder. Arch. Gen. Psychiatry 67(10), 1061-1068 (2010).
18. Liu K, Zhang H, Liu C et al. Stereotactic treatment of refractory obsessive compulsive disorder by bilateral capsulotomy with 3 years follow-up. J. Clin. Neurosci. 15(6), 622-629 (2008).
19. McDougle CJ, Barr LC, Goodman WK et al. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am. J. Psychiatry 152(12), 1812-1814 (1995).
20. Connor KM, Payne VM, Gadde KM, Zhang W, Davidson Jr. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J. Clin. Psychiatry 66(1), 49-51 (2005).
21. Sayyah M, Sayyah M, Boostani H, Ghaffari SM, Hoseini A. Effects of aripiprazole augmentation in treatmentresistant obsessive-compulsive disorder (a double blind clinical trial). Depress. Anxiety 29(10), 850-854 (2012).
22. Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatmentresistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. Int. J. Neuropsychopharmacol. 1-18 (2012).
23. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol. Psychiatry 11(7), 622-632 (2006). (Pubitemid 43989810)
24. Skapinakis P, Papatheodorou T, Mavreas V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a metaanalysis of the randomized controlled trials. Eur. Neuropsychopharmacol. 17(2), 79-93 (2007). (Pubitemid 44779187)
25. Dold M, Aigner M, Lanzenberger R, Kasper S. Efficacy of antipsychotic augmentation therapy in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomised, placebo-controlled trials. Fortschr. Neurol. Psychiatr. 79(8), 453-466 (2011).
26. Komossa K, Depping AM, Meyer M, Kissling W, Leucht S. Second-generation antipsychotics for obsessive compulsive disorder. Cochrane Database Syst. Rev. 12, CD008141 (2010).
27. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxaminerefractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch. Gen. Psychiatry 51(4), 302-308 (1994). (Pubitemid 24127303)
28. McDougle CJ, Goodman WK, Price LH et al. Neuroleptic addition in fluvoxaminerefractory obsessive-compulsive disorder. Am. J. Psychiatry 147(5), 652-654 (1990). (Pubitemid 20153442)
29. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitorrefractory obsessive-compulsive disorder. Arch. Gen. Psychiatry 57(8), 794-801 (2000). (Pubitemid 30650116)
30. Shapira NA, Ward HE, Mandoki M et al. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol. Psychiatry 55(5), 553-555 (2004). (Pubitemid 38338545)
31. Carey PD, Vythilingum B, Seedat S, Muller JE, van Ameringen M, Stein DJ. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. BMC Psychiatry 5, 5 (2005).
32. Bogetto F, Bellino S, Vaschetto P, Ziero S. Olanzapine augmentation of fluvoxaminerefractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res. 96(2), 91-98 (2000).
33. Buchsbaum MS, Hollander E, Pallanti S et al. Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients. Neuropsychobiology 53(3), 157-168 (2006). (Pubitemid 43854176)
34. Saxena S, Brody AL, Ho ML, Zohrabi N, Maidment KM, Baxter LR Jr. Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. Am. J. Psychiatry 160(3), 522-532 (2003). (Pubitemid 41094261)
35. Fineberg NA, Gale TM, Sivakumaran T. A review of antipsychotics in the treatment of obsessive compulsive disorder. J. Psychopharmacol. (Oxford) 20(1), 97-103 (2006).
36. Carey PD, Lochner C, Kidd M, Van Ameringen M, Stein DJ, Denys D. Quetiapine augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: is response to treatment predictable? Int. Clin. Psychopharmacol. 27(6), 321-325 (2012).
37. Vulink NC, Denys D, Fluitman SB, Meinardi JC, Westenberg HG. Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo- controlled study of 76 patients. J. Clin. Psychiatry 70(7), 1001-1008 (2009).
38. Hollander E, Baldini Rossi N, Sood E, Pallanti S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int. J. Neuropsychopharmacol. 6(4), 397-401 (2003). (Pubitemid 38146258)
39. Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive- compulsive disorder: a double-blind, placebo-controlled study. Eur. Neuropsychopharmacol. 15(1), 69-74 (2005). (Pubitemid 39574401)
40. Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive- compulsive disorder: a crossover study. J. Clin. Psychiatry 66(6), 736-743 (2005). (Pubitemid 40942420)
41. Saxena S, Wang D, Bystritsky A, Baxter LR Jr. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J. Clin. Psychiatry 57(7), 303-306 (1996). (Pubitemid 26251110)
42. Stein DJ, Bouwer C, Hawkridge S, Emsley RA. Risperidone augmentation of serotonin reuptake inhibitors in obsessive- compulsive and related disorders. J. Clin. Psychiatry 58(3), 119-122 (1997). (Pubitemid 27149253)
43. Denys D, de Geus F, van Megen HJ, Westenberg HG. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients withobsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J. Clin. Psychiatry 65(8), 1040-1048 (2004).
44. Fineberg NA, Sivakumaran T, Roberts A, Gale T. Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int. Clin. Psychopharmacol. 20(4), 223-226 (2005). (Pubitemid 40896377)
45. Kordon A, Wahl K, Koch N et al. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive- compulsive disorder: a double-blind, randomized, placebo-controlled study. J. Clin. Psychopharmacol. 28(5), 550-554 (2008).
46. Atmaca M, Kuloglu M, Tezcan E, Gecici O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int. Clin. Psychopharmacol. 17(3), 115-119 (2002). (Pubitemid 34442192)
47. Denys D, van Megen H, Westenberg H. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. J. Clin. Psychiatry 63(8), 700-703 (2002).
48. Mohr N, Vythilingum B, Emsley RA, Stein DJ. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive- compulsive disorder. Int. Clin. Psychopharmacol. 17(1), 37-40 (2002). (Pubitemid 34056524)
49. Koran LM, Ringold AL, Elliott MA. Olanzapine augmentation for treatmentresistant obsessive-compulsive disorder. J. Clin. Psychiatry 61(7), 514-517 (2000). (Pubitemid 30483423)
50. Bystritsky A, Ackerman DL, Rosen RM et al. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J. Clin. Psychiatry 65(4), 565-568 (2004).
51. Maina G, Pessina E, Albert U, Bogetto F. 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive- compulsive disorder. Eur. Neuropsychopharmacol. 18(5), 364-372 (2008).
52. Matsunaga H, Hayashida K, Maebayashi K, Mito H, Kiriike N. A case series of aripiprazole augmentation of selective serotonin reuptake inhibitors in treatmentrefractory obsessive compulsive disorder. Int. J. Psychiatry Clin. Pract. 15(4), 263-269 (2011).
53. Higuma H, Kanehisa M, Maruyama Y et al. Aripiprazole augmentation in 13 patients with refractory obsessive-compulsive disorder: a case series. World J. Biol. Psychiatry 13(1), 14-21 (2012).
54. Muscatello MR, Bruno A, Pandolfo G et al. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive- compulsive disorder: a double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 31(2), 174-179 (2011).
55. Metin O, Yazici K, Tot S, Yazici AE. Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial. Hum. Psychopharmacol. 18(6), 463-467 (2003). (Pubitemid 37038343)
56. Maina G, Albert U, Ziero S, Bogetto F. Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued? Int. Clin. Psychopharmacol. 18(1), 23-28 (2003). (Pubitemid 36127057)
57. Marazziti D, Pfanner C, Dell'Osso B et al. Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study. J. Psychopharmacol. (Oxford) 19(4), 392-394 (2005). (Pubitemid 41003135)
58. Matsunaga H, Nagata T, Hayashida K, Ohya K, Kiriike N, Stein DJ. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. J. Clin. Psychiatry 70(6), 863-868 (2009).
59. Lykouras L, Alevizos B, Michalopoulou P, Rabavilas A. Obsessive-compulsive symptoms induced by atypical antipsychotics. A review of the reported cases. Prog. Neuropsychopharmacol. Biol. Psychiatry 27(3), 333-346 (2003). (Pubitemid 36403724)
60. Schirmbeck F, Zink M. Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review. Curr. Neuropharmacol. 10(1), 88-95 (2012).
61. Ramasubbu R, Ravindran A, Lapierre Y. Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs. Pharmacopsychiatry 33(6), 236-238 (2000).
62. Marek GJ, Carpenter LL, McDougle CJ, Price LH. Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology 28(2), 402-412 (2003).
63. Soltani F, Sayyah M, Feizy F, Malayeri A, Siahpoosh A, Motlagh I. A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. Hum. Psychopharmacol. 25(6), 509-513 (2010).
64. Askari N, Moin M, Sanati M et al. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. CNS Drugs 26(10), 883-892 (2012).
65. Koran LM, Gamel NN, Choung HW, Smith EH, Aboujaoude EN. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J. Clin. Psychiatry 66(4), 515-520 (2005). (Pubitemid 40593581)
66. Pallanti S, Quercioli L, Bruscoli M. Response acceleration with mirtazapine augmentation of citalopram in obsessive- compulsive disorder patients without comorbid depression: a pilot study. J. Clin. Psychiatry 65(10), 1394-1399 (2004).
67. Pallanti S, Quercioli L, Paiva RS, Koran LM. Citalopram for treatment-resistant obsessive-compulsive disorder. Eur. Psychiatry 14(2), 101-106 (1999).
68. Marazziti D, Golia F, Consoli G et al. Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients. CNS Spectr. 13(11), 971-976 (2008).
69. Diniz JB, Shavitt RG, Pereira CA et al. Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial. J. Psychopharmacol. (Oxford) 24(3), 297-307 (2010).
70. Grady TA, Pigott TA, L'Heureux F, Hill JL, Bernstein SE, Murphy DL. Doubleblind study of adjuvant buspirone for fluoxetine-treated patients with obsessive- compulsive disorder. Am. J. Psychiatry 150(5), 819-821 (1993). (Pubitemid 23137694)
71. Crockett BA, Churchill E, Davidson Jr. A double-blind combination study of clonazepam with sertraline in obsessive- compulsive disorder. Ann. Clin. Psychiatry 16(3), 127-132 (2004). (Pubitemid 39281271)
72. Hewlett WA, Vinogradov S, Agras WS. Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder. J. Clin. Psychopharmacol. 12(6), 420-430 (1992).
73. Hollander E, Kaplan A, Stahl SM. A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder. World J. Biol. Psychiatry 4(1), 30-34 (2003).
74. Dannon PN, Sasson Y, Hirschmann S, Iancu I, Grunhaus LJ, Zohar J. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a doubleblind placebo controlled trial. Eur. Neuropsychopharmacol. 10(3), 165-169 (2000). (Pubitemid 30227616)
75. Mundo E, Guglielmo E, Bellodi L. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study. Int. Clin. Psychopharmacol. 13(5), 219-224 (1998). (Pubitemid 28470313)
76. Pigott TA, L'Heureux F, Rubenstein CS, Bernstein SE, Hill JL, Murphy DL. A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder. J. Clin. Psychopharmacol. 12(3), 156-162 (1992).
77. Pittenger C, Bloch MH, Williams K. Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol. Ther. 132(3), 314-332 (2011).
78. Grant P, Lougee L, Hirschtritt M, Swedo SE. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J. Child Adolesc. Psychopharmacol. 17(6), 761-767 (2007). (Pubitemid 351158597)
79. Coric V, Taskiran S, Pittenger C et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol. Psychiatry 58(5), 424-428 (2005). (Pubitemid 41219711)
80. Aboujaoude E, Barry JJ, Gamel N. Memantine augmentation in treatmentresistant obsessive-compulsive disorder: an open-label trial. J. Clin. Psychopharmacol. 29(1), 51-55 (2009).
81. Stewart SE, Jenike EA, Hezel DM et al. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J. Clin. Psychopharmacol. 30(1), 34-39 (2010).
82. Ghaleiha A, Entezari N, Modabbernia A et al. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J. Psychiatr. Res. (2012).
83. Bruno A, Micò U, Pandolfo G et al. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a doubleblind, placebo-controlled study. J. Psychopharmacol. (Oxford) 26(11), 1456-1462 (2012).
84. Mowla A, Khajeian AM, Sahraian A, Chohedri AH, Kashkoli F. Topiramate augmentation in resistant OCD: a doubleblind placebo-controlled clinical trial. CNS Spectr. (2010) (Epub ahead of print).
85. Berlin HA, Koran LM, Jenike MA et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatmentresistant obsessive-compulsive disorder. J. Clin. Psychiatry 72(5), 716-721 (2011).
86. Oulis P, Mourikis I, Konstantakopoulos G. Pregabalin augmentation in treatmentresistant obsessive-compulsive disorder. Int. Clin. Psychopharmacol. 26(4), 221-224 (2011).
87. Di Nicola M, Tedeschi D, Martinotti G et al. Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder: a 16-week case series. J. Clin. Psychopharmacol. 31(5), 675-677 (2011).
88. Onder E, Tural U, Gökbakan M. Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder? Eur. Arch. Psychiatry Clin. Neurosci. 258(6), 319-323 (2008).
89. Bloch MH, Wasylink S, Landeros-Weisenberger A et al. Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol. Psychiatry 72(11), 964-970 (2012).
90. Greenberg WM, Benedict MM, Doerfer J et al. Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults. J. Psychiatr. Res. 43(6), 664-670 (2009).
91. Wu PL, Tang HS, Lane HY, Tsai CA, Tsai GE. Sarcosine therapy for obsessive compulsive disorder: a prospective, open-label study. J. Clin. Psychopharmacol. 31(3), 369-374 (2011).
92. Koran LM, Aboujaoude E, Gamel NN. Double-blind study of dextroamphetamine versus caffeine augmentation for treatmentresistant obsessive-compulsive disorder. J. Clin. Psychiatry 70(11), 1530-1535 (2009).
93. McDougle CJ, Price LH, Goodman WK, Charney DS, Heninger GR. A controlled trial of lithium augmentation in fluvoxamine- refractory obsessive-compulsive disorder: lack of efficacy. J. Clin. Psychopharmacol. 11(3), 175-184 (1991).
94. Fux M, Levine J, Aviv A, Belmaker RH. Inositol treatment of obsessive-compulsive disorder. Am. J. Psychiatry 153(9), 1219-1221 (1996). (Pubitemid 26299846)
95. Fux M, Benjamin J, Belmaker RH. Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a doubleblind cross-over study. Int. J. Neuropsychopharmacol. 2(3), 193-195 (1999).
96. Koran LM, Aboujaoude E, Bullock KD, Franz B, Gamel N, Elliott M. Doubleblind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J. Clin. Psychiatry 66(3), 353-359 (2005). (Pubitemid 40476759)
97. Amiaz R, Fostick L, Gershon A, Zohar J. Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study. Eur. Neuropsychopharmacol. 18(6), 455-461 (2008).
98. Albert U, Barbaro F, Aguglia A, Maina G, Bogetto F. Combined treatments in obsessive-compulsive disorder: current knowledge and future prospects. Riv. Psichiatr. 47(4), 255-268 (2012).
99. Foa EB, Liebowitz MR, Kozak MJ et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am. J. Psychiatry 162(1), 151-161 (2005). (Pubitemid 40095685)
100. The Pediatric OCD Treatment Study (POTS) Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive- compulsive disorder: the pediatric OCD treatment study (POTS) randomized controlled trial. JAMA 292(16), 1969-1976 (2004).
101. Tundo A, Salvati L, Busto G, Di Spigno D, Falcini R. Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study. J. Clin. Psychiatry 68(10), 1552-1556 (2007). (Pubitemid 350073404)
102. Anand N, Sudhir PM, Math SB, Thennarasu K, Janardhan Reddy YC. Cognitive behavior therapy in medication non-responders with obsessive-compulsive disorder: a prospective 1-year follow-up study. J. Anxiety Disord. 25(7), 939-945 (2011).
103. Tolin DF, Hannan S, Maltby N, Diefenbach GJ, Worhunsky P, Brady RE. A randomized controlled trial of self-directed versus therapist-directed cognitive-behavioral therapy for obsessive-compulsivedisorder patients with prior medication trials. Behav. Ther. 38(2), 179-191 (2007). (Pubitemid 46711183)
104. Simpson HB, Foa EB, Liebowitz MR et al. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. Am. J. Psychiatry 165(5), 621-630 (2008). (Pubitemid 351705340)
105. Franklin ME, Sapyta J, Freeman JB et al. Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive- compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial. JAMA 306(11), 1224-1232 (2011).
106. Blom RM, Figee M, Vulink N, Denys D. Update on repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: different targets. Curr. Psychiatry Rep. 13(4), 289-294 (2011).
107. Mantovani A, Simpson HB, Fallon BA, Rossi S, Lisanby SH. Randomized sham-controlled trial of repetitive transcranial magnetic stimulation in treatment-resistant obsessive-compulsive disorder. Int. J. Neuropsychopharmacol. 13(2), 217-227 (2010).
108. Kang JI, Kim CH, Namkoong K, Lee CI, Kim SJ. A randomized controlled study of sequentially applied repetitive transcranial magnetic stimulation in obsessive-compulsive disorder. J. Clin. Psychiatry 70(12), 1645-1651 (2009).
109. Slotema CW, Blom JD, Hoek HW, Sommer IE. Should we expand the toolbox of psychiatric treatment methods to include repetitive transcranial magnetic stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. J. Clin. Psychiatry 71(7), 873-884 (2010).
110. Greenberg BD, Price LH, Rauch SL et al. Neurosurgery for intractable obsessive- compulsive disorder and depression: critical issues. Neurosurg. Clin. N. Am. 14(2), 199-212 (2003). (Pubitemid 36514460)
111. Lopes AC, Mathis ME, Canteras MM, Salvajoli JV, Del Porto JA, Miguel EC. Update on neurosurgical treatment for obsessive compulsive disorder. Revista Brasileira de Psiquiatria. 26(1), 62-66 (2004). (Pubitemid 38419361)
112. Greenberg BD, Rauch SL, Haber SN. Invasive circuitry-based neurotherapeutics: stereotactic ablation and deep brain stimulation for OCD. Neuropsychopharmacology 35(1), 317-336 (2010).
113. Leiphart JW, Valone FH 3rd. Stereotactic lesions for the treatment of psychiatric disorders. J. Neurosurg. 113(6), 1204-1211 (2010).
114. Bourne SK, Eckhardt CA, Sheth SA, Eskandar EN. Mechanisms of deep brain stimulation for obsessive compulsive disorder: effects upon cells and circuits. Front. Integr. Neurosci. 6, 29 (2012).
115. Blomstedt P, Sjöberg RL, Hansson M, Bodlund O, Hariz MI. Deep brain stimulation in the treatment of obsessive- compulsive disorder. World Neurosurg. (2012).
116. Bhattacharyya S, Chakraborty K. Glutamatergic dysfunction - newer targets for anti-obsessional drugs. Recent Pat. CNS Drug Discov. 2(1), 47-55 (2007). (Pubitemid 46729090)
117. Goddard AW, Shekhar A, Whiteman AF, McDougle CJ. Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder. Drug Discov. Today 13(7-8), 325-332 (2008).
118. Fontenelle LF, Guimarães Barbosa I, Victor Luna J, Pessoa Rocha N, Silva Miranda A, Lucio Teixeira A. Neurotrophic factors in obsessive-compulsive disorder. Psychiatry Res. 199(3), 195-200 (2012).
119. Schmidt HD, Duman RS. Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology 35(12), 2378-2391 (2010).
120. NICE. CG31 Obsessive-compulsive disorder: NICE guideline [Internet]. http://publications.nice.org.uk/obsessive- compulsive-disorder-cg31